Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia

2021 ◽  
Author(s):  
Justin H. Reid ◽  
Bernard L. Marini ◽  
Lydia L. Benitez ◽  
Kristen Pettit ◽  
Dale L. Bixby ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Propensity Score ◽  
Myeloid Leukemia ◽  
Salvage Chemotherapy ◽  
Refractory Acute Myeloid Leukemia ◽  
Matched Comparison ◽  
Acute Myeloid

scholarly journals A Rare Case of Coexisting Breast Cancer and Refractory Acute Myeloid Leukemia

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
L. Ballotta ◽  
S. M. Trisolini ◽  
A. P. Iori ◽  
U. La Rocca ◽  
A. Micozzi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Salvage Chemotherapy ◽  
Infectious Complications ◽  
Term Survival ◽  
First Line Therapy ◽  
Refractory Acute Myeloid Leukemia ◽  
Acute Myeloid

The occurrence of acute myeloid leukemia (AML) within six months from a diagnosis of breast cancer (BC) is rarely reported in the literature, and it is associated with a poor prognosis. We report herein the case of a 40-year-old woman referred to our centre affected by BC and simultaneous AML. The patient proved refractory to first line therapy and achieved complete remission (CR) with a clofarabine-based regimen followed by allogeneic stem cell transplantation (ASCT). Both during salvage chemotherapy and after ASCT, the patient presented severe infectious complications ( acute cholecistytis and Nocardia pneumonia, respectively) treated with surgery, and currently she is alive in CR for both diseases after 29 months of follow-up. The case highlights the importance of a diagnostic assessment of any unexplained cytopenia in association with solid neoplasia under treatment, underlining the feasibility and priority of a timely treatment of the haematological neoplasm in order to achieve long-term survival.

scholarly journals Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

2019 ◽  
Author(s):  
Bogdan Popescu ◽  
Sheenu Sheela ◽  
Julie Thompson ◽  
Sophia Grasmeder ◽  
Therese Intrater ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Salvage Chemotherapy ◽  
Refractory Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS

2012 ◽  
Vol 4 (1) ◽  
pp. e2012072 ◽  
Author(s):  
Saveria Capria ◽  
Silvia Maria Trisolini ◽  
Clara Minotti ◽  
Caterina Stefanizzi ◽  
Luisa Cardarelli ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Salvage Chemotherapy ◽  
Gemtuzumab Ozogamicin ◽  
Treatment Schedule ◽  
Term Survival ◽  
Bridge To Transplant ◽  
Refractory Acute Myeloid Leukemia ◽  
Acute Myeloid

Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation.We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant.Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation

2020 ◽  
Author(s):  
Octavio Ballesta-López ◽  
Antonio Solana-Altabella ◽  
Juan Eduardo Megías-Vericat ◽  
David Martínez-Cuadrón ◽  
Pau Montesinos
Keyword(s):  
Acute Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Salvage Chemotherapy ◽  
Mechanisms Of Resistance ◽  
Flt3 Inhibitor ◽  
Refractory Acute Myeloid Leukemia ◽  
Dose Reductions ◽  
Acute Myeloid

The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is dismal with salvage standard approaches, and mutations of FMS-like tyrosine kinase 3 ( FLT3) gene, occurring in around 30% of AML patients may confer even poorer outcomes. Several targeted tyrosine kinase inhibitors have been developed to improve FLT3-mutated AML patient´s survival. Gilteritinib, a highly specific second-generation class I oral FLT3 inhibitor, has demonstrated superiority to salvage chemotherapy (SC) in R/R FLT3 mutated AML based on significantly longer OS in the gilteritinib arm than in the SC arm. Gilteritinib is generally well tolerated, but some clinically relevant adverse events should be monitored, especially myelosuppression, QTc prolongation and differentiation syndrome, usually manageable (dose reductions, interruption or discontinuation) and reversible. We discuss clinical development, efficacy, safety and mechanisms of resistance of gilteritinib in the treatment of R/R patients with FLT3 mutated AML.

Sign in / Sign up

Export Citation Format

Share Document